Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Inclusion Criteria:

* Histologically confirmed sarcoma that is recurrent or refractory to conventional treatment
* Measurable disease by RECIST criteria
* ECOG (Eastern Cooperative Oncology Group) performance status \< 2 (or Lansky/Karnofsky \> 60% for children)
* Life expectancy greater than 3 months
* Adequate organ function
* absolute neutrophil count at least 1,500
* platelets at least 100,000
* bilirubin less than 1.5 x upper limit of normal
* AST (aspartate aminotransferase) and ALT(alanine aminotransferase) less than 2.5 x upper limit of normal
* creatinine less than 1.5 x upper limit of normal OR creatinine clearance at least 60 ml/min/1.73 m2
* fasting serum cholesterol less than 350
* fasting serum triglycerides less than 400
* PT (prothrombin) or INR (international normalized ratio) less than 1.3 x upper limit of normal
* normal urinalysis
* Ability to understand and sign the informed consent document

Exclusion Criteria:

* Prior chemotherapy or radiotherapy within 3 weeks of entering the study (6 weeks for nitrosoureas or mitomycin C)
* Prior treatment with a tyrosine kinase inhibitor within 10 days of entering the study
* History of pulmonary hypertension or pneumonitis
* Patients may not be receiving other investigational agents
* Prior therapy with rapamycin, rapamycin analogues, or tacrolimus
* Uncontrolled brain metastases
* History of grade 3 or 4 hypersensitivity to macrolide antibiotics
* Concurrent treatment with immunosuppressive agents other than a stable (for more than 2 weeks) dose of corticosteroids
* Uncontrolled intercurrent illness
* Pregnancy or breast feeding
* HIV-positive patients on combination antiretroviral therapy
* Grade 3 or 4 proteinuria